Date: 2018-04-12
Type of information: Nomination
Compound: chief executive officer
Company: BioInvent (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 31, 2018 , BioInvent announced that Martin Welschof will officially take office as Chief Executive Officer on 1 September. Björn Frendéus, acting CEO of BioInvent since 1 January, 2018, will resume his fulltime role of Chief Scientific Officer.
- • On April 12, 2018, BioInvent announced that Dr Martin Welschof has been appointed new President and CEO. He will take office within five months to allow for conclusion of ongoing business discussions at Opsona Therapeutics. Martin Welschof has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience (Germany) and CEO of Affitech (Nasdaq Copenhagen). He is currently CEO of Opsona Therapeutics, based in Dublin, Ireland.
- In addition, he has a strong scientific background in the field of antibody technology. He did his post-doctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Martin earned his Ph.D. (Dr.rer.nat.) in the field of recombinant antibody technology from the University of Bielefeld, in Germany.
Financial terms:
Latest news:
Is general: Yes
